
Vijaya Diagnostic Centre Q3 FY24 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
Yes
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 3- The company expects a 14% to 15% growth primarily driven by volume growth (around 15% test volume growth).
- Non-COVID revenue grew 17% YoY, with 18% volume growth including PH acquisition impact.
- Volume growth is driven by both existing and new centers across geographies including Hyderabad, Pune, Kolkata, and Tier-2/ Tier-3 cities.
- Hyderabad remains a key growth market expected to sustain high double-digit growth for the next 2-3 years.
- The contribution from Hyderabad, currently ~80%, is expected to reduce to approximately 70-75% as other markets like Andhra, Pune, and Eastern India grow.
- PH Pune acquisition (~Rs.42 crores revenue in FY23) is expected to grow further and contribute to revenue scaling.
- The company plans to continue adding 12-15 centers annually, with expansion focused on existing and adjacent geographies.
- Price hikes are limited (~1-1.5% annually); growth is volume-driven rather than price-driven.
See what Vijaya Diagnostic Centre management said on margin guidance — free account, 30 seconds.
Fundraise plans
- There is no mention of any current or planned fundraising through debt or equity in the transcript.
- The company funded the PH Diagnostics acquisition (₹147.50 crores) entirely through existing cash reserves.
- Post-acquisition and dividend payment, the cash reserve stands at ₹158 crores.
- The strong cash position and healthy balance sheet are highlighted as supporting future expansion.
- No indications were given about raising additional capital via equity or debt at this time.
See what Vijaya Diagnostic Centre management said on order book — free account, 30 seconds.
Capex plans
Yes- The company continues to expand into new geographies following a well-thought-out expansion strategy.
- Recent significant acquisition: PH Diagnostics in Pune for Rs.147.5 crores, fully funded from existing cash reserves.
- The company is close to reaching 150 centers across 23 cities and 5 states.
- New hub centers recently launched at Mahbubnagar and Gulbarga as part of Tier-2 city and adjacent geography expansion.
- Additional two spokes added in Hyderabad network in the recent year.
- Plans to open 12 to 15 centers annually remain intact, although some may spill over to the next financial year due to delays.
- Expect increased CAPEX in Pune region with 2-3 hubs expected after acquisition integration.
- In Kolkata, gradual, organic growth with 1 hub opening every two quarters; East India expansion continues at a measured pace.
- The company is focusing on integrating PH's operations fully in the next two quarters, including front-end and back-end processes.
Track Vijaya Diagnostic Centre — get its next earnings analysis in your feed
How does Vijaya Diagnostic Centre rank vs peers in Healthcare Services?
Pro featureHow does Vijaya Diagnostic Centre rank in Healthcare Services?
Compare Vijaya Diagnostic Centre against every Healthcare Services company (Q3 FY24) on revenue, margins and earnings-call signals.
Continue your research
What Vijaya Diagnostic Centre's management said in earlier quarters
Others in Healthcare Services this season
- Chandan Healthca (Q2 FY27)
Q2 FY27 operating income: ₹57.94 Cr, up 45.04% YoY from ₹39.95 Cr (Page 8) . Key investor presentation takeaways from Chandan Healthcare Ltd's Q2 FY27 investor
- Invicta Diagnostic (Q2 FY27)
Revenue from operations for the half year ended September 30, 2026: ₹379.11 lakhs (Page 4). Key results statement takeaways from Invicta Diagnostic Ltd's Q2 FY2
- Unihealth Hosp (Q2 FY27)
1,270 million with a year-on-year (YoY) growth of 6.3% . Key results statement takeaways from Unihealth Hospitals Ltd's Q2 FY27 results statement — and how it r
- Sangani Hospital (Q2 FY27)
1008.56 lakhs (~11.8% increase). Key results statement takeaways from Sangani Hospitals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.